LRRC66 Inhibitors
LRRC66 inhibitors belong to a distinct chemical class characterized by their ability to modulate the activity of leucine-rich repeat-containing protein 66 (LRRC66). LRRC66 is a protein that contains leucine-rich repeats, which are structural motifs known for their involvement in protein-protein interactions. The inhibitors targeting LRRC66 typically act by binding to specific sites on the protein, thereby altering its conformation or blocking its functional domains. These compounds are designed to selectively inhibit LRRC66's biological activity, which may play a role in various cellular processes and signaling pathways.
Structurally, LRRC66 inhibitors exhibit diverse chemical architectures, encompassing a range of organic and inorganic compounds. The design and development of these inhibitors involve a thorough understanding of the molecular interactions between the inhibitor and LRRC66. Researchers employ various computational and experimental techniques to identify potential binding sites and optimize the chemical structure of the inhibitors for enhanced specificity and efficacy. The elucidation of the crystal structures of LRRC66 in complex with inhibitors has provided valuable insights into the molecular mechanisms underlying their inhibitory effects.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases, including protein kinase C, which is involved in the regulation of various proteins. Inhibition of this kinase would decrease phosphorylation events that may indirectly lead to the functional inhibition of LRRC66, assuming LRRC66 is regulated by phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks). PI3K signaling is crucial in many cellular processes, and its inhibition can result in altered cell survival and protein regulation. This could indirectly lead to decreased LRRC66 function if LRRC66 is part of a pathway downstream of PI3K. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, which is part of the PI3K/AKT/mTOR pathway, it can indirectly affect protein synthesis. If LRRC66 synthesis is regulated by this pathway, then rapamycin could lead to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. Inhibition of MEK can lead to decreased activation of ERK, potentially affecting proteins that are regulated through this pathway, which could include an indirect inhibition of LRRC66. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can modulate inflammatory responses and apoptosis, which may indirectly inhibit LRRC66 if it is affected by these cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress responses. By inhibiting JNK, SP600125 could indirectly influence the functional activity of LRRC66 if LRRC66 is part of stress response signaling pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If LRRC66 is regulated by ubiquitin-proteasome-mediated degradation, MG132 could lead to indirect inhibition by accumulation of LRRC66, possibly affecting its proper function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor, similar in function to MG132. Inhibition of the proteasome could result in an indirect functional inhibition of LRRC66 by altering its degradation pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, it can affect numerous cellular processes by inhibiting this kinase, potentially leading to an indirect decrease in LRRC66 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go6983 is a protein kinase C inhibitor. By inhibiting protein kinase C, it could potentially decrease phosphorylation events that regulate the function of various proteins, which may include an indirect inhibition of LRRC66. | ||||||